IP Library › Granted Patent US 12,232,949
Granted Patent B2
US 12,232,949 · App. 16/080,852 · Granted Feb 25, 2025

Method of endogenous stem cell activation for tendon/ligament osseointegration

Inventors: Dan Gazit (Los Angeles, CA); Gadi Pelled (Los Angeles, CA); Thomas Kremen (Los Angeles, CA)
Assignee: Cedars-Sinai Medical Center
A61F2/08A61K38/1875A61L27/24A61L27/54A61L2300/258A61L2300/414A61L2430/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,232,949
App. No.
16/080,852
Granted
Feb 25, 2025
Kind
B2
Abstract

Tendon and ligament injuries are common in orthopaedic clinical practice and cause substantial morbidity in sports and in routine daily activities. While surgical reconstruction is effective, the majority of patients suffer from a prolonged period of recovery because of limited regeneration capacity of the tendon-bone interface. Here, the Inventors have established an approach for promoting tendon/ligament integration. By first recruiting endogenous stem cells to the site of injury, bone morphogenic proteins (BMPs), are then delivered in vivo to promote repair. Significant acceleration of healing via the above methods and compositions leads to fast recovery and return to normal activities, thereby providing new therapeutic avenues for treatment of injuries involving the tendon-bone interface.

Claims (23)

1. A method of promoting osseointegration in a soft-tissue structure injury of the musculoskeletal system of a patient, comprising the steps of:

administering an agent comprising a collagen scaffold at an injured soft-tissue site of the musculoskeletal system of a patient, the injured soft-tissue site comprising an interface of: (i) bone and (ii) tendon or ligament,

wherein the injured soft-tissue site comprises injured soft-tissue,

wherein the soft tissue site includes one or more bone tunnel;

recruiting endogenous mesenchymal stem cells to the injured soft-tissue site by the agent comprising a collagen scaffold;

delivering a non-viral composition comprising 0.6-1.0 mg of bone morphogenic protein-6 (BMP-6) encoding plasmid suspended in 10 5 -10 8 microbubbles per 1-3 cm 3 of one or more bone tunnel at the injured soft-tissue site,

wherein the non-viral composition is delivered 14 days after administration of the agent comprising the collagen scaffold;

applying ultrasound to the injured soft-tissue site after delivery of the non-viral composition; and visualizing microbubble oscillation using ultrasound imaging,

wherein the recruited endogenous mesenchymal stem cells at the injured soft-tissue site are transfected with the delivered non-viral composition and express BMP-6; and

wherein the injured soft-tissue is selected from the group consisting of anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament of the knee, medial collateral ligament of the elbow, lateral collateral ligament of the knee, lateral colla teral ligament of the elbow, and rotator cuff tendon.

2. The method of claim 1 , wherein the non-viral composition comprising 0.6-1.0 mg of BMP-6 encoding plasmid suspended in 10 5 -10 8 microbubbles per 1-3 cm 3 of one or more bone tunnel at the injured soft-tissue site is delivered in only one dose.

3. The method of claim 1 , wherein applying ultrasound to the injured soft-tissue site is completed with a transmission frequency of 1.0-1.5 MHz.

4. The method of claim 1 , wherein applying ultrasound to the injured soft-tissue site is completed with a mechanical index of 0.3-0.9.

5. The method of claim 1 , wherein applying ultrasound to the injured soft-tissue site is completed for 30 seconds to 5 minutes.

6. The method of claim 1 , wherein applying ultrasound to the injured soft-tissue site is completed with a transmission frequency of 1.3 MHz, a mechanical index of 0.6, and a depth of 4 cm for approximately 2 minutes until all visualized microbubbles of the non-viral composition burst.

7. The method of claim 1 , wherein applying ultrasound to the injured soft-tissue site is completed until all visualized microbubbles of the non-viral composition burst.

8. The method of claim 1 , further comprising the step of measuring osseointegration via computer tomography scan or magnetic resonance imaging after applying ultrasound to the injured soft-tissue site.

9. The method of claim 1 , further comprising locating the injured soft-tissue site using fluoroscopic imaging prior to delivering the non-viral composition.

10. The method of claim 1 , wherein the non-viral composition includes 1.0 mg of BMP-6 encoding plasmid suspended in 10 7 microbubbles per 1-3 cm 3 of one or more bone tunnel.

11. The method of claim 1 , wherein the recruited endogenous mesenchymal stem cells populate the collagen scaffold at the injured soft-tissue site.

12. The method of claim 1 , wherein the non-viral composition is delivered to the injured soft-tissue site through a needle of a syringe.

13. The method of claim 12 , further comprising placing an ultrasound probe adjacent to the needle for visualization of the delivered non-viral composition and for applying ultrasound to the injured soft-tissue site.

14. The method of claim 13 , wherein microbubble oscillation is monitored using ultrasound imaging while applying ultrasound to the injured soft-tissue site at which the non-viral composition has been delivered.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 17, 2021
From: CEDARS-SINAI MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 057538/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: GAZIT, DAN; PELLED, GADI; KREMEN, THOMAS
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 046741/0353 →
Continuity (2)
Provisional Application 62301176 · Feb 29, 2016
Related Publication 20190083231A1 · Mar 21, 2019
References Cited (40)
US 5763416A · Bonadio et al. · 1998 [cited by examiner]
US 8870954B2 · Lynch et al. · 2014 [cited by applicant]
US 20110124716A1 · Passineau · 2011 [cited by applicant]
US 20140178346A1 · James et al. · 2014 [cited by applicant]
US 20140277569A1 · Lange · 2014 [cited by examiner]
US 20150320519A1 · Suttin et al. · 2015 [cited by applicant]
CN 101385851A · 2009 [cited by applicant]
CN 102231992A · 2011 [cited by applicant]
CN 2017800138263 · 2018 [cited by applicant]
EP 2674172A1 · 2013 [cited by applicant]
JP 2019510750 · 2019 [cited by applicant]
WO 2003029429A2 · 2003 [cited by applicant]
WO 2017151674A · 2017 [cited by applicant]
Park et al., Biomaterials 28 (2007) 2772-2782. [cited by examiner]
Betz et al., Gene Therapy, 14: 1039-1044, 2007. [cited by examiner]
Ratcliffe et al., Annals of Biomedical Engineering, vol. 43, No. 3, Mar. 2015 ( 2015) pp. 819-831. [cited by examiner]
Kang et al. Characterization of the distinct orthotopic bone-forming activity of 15 BMPs using recombinant adenovirus-mediated gene delivery, Gene Therapy, 11: 1312-1320. (Year: 2004). [cited by examiner]
Watrin-Pinzano, et al., Evaluation of cartilage repair tissue after biomaterial implantation in rat patella by using T2 mapping, Magnetic Resonance Materials in Physics, Biology and Medicine, 17: 219-228 (Year: 2004). [cited by examiner]
Delalande et al., Sonoporation: mechanism insights and ongoing challenges for gene transfer, Gene, 525: 191-199. (Year: 2013). [cited by examiner]
Umebayasi et al., Gene-activated matrix comprised of atelocollagen and plasmid DBA encoding BMP4 or Runx2 promotes rat cranial bone augmentation, BioResearch Open Access, 4.1:164-174. (Year: 2015). [cited by examiner]
Shoaib et al., A comparison of radiation exposure with the conventional versus mini C arm in orthopedic extremity surgery, Foot and Ankle international, p. 58-61. (Year: 2008). [cited by examiner]
Hoher et al., Bone tunnel enlargement after anterior cruciate ligament reconstruction: fact or fiction?, Knee Surg, Sports Traumatol, Arthrosc, 6: 231-240. (Year: 1998). [cited by examiner]
Shapiro et al., Ultrasound-mediated transgene expression in endogenous stem cells recruited to bone injury sites, Polymers Advanced Technologies, p. 1-7. (Year: 2014). [cited by examiner]
Sheyn et al., Ultrasound-based nonviral gene delivery induces bone formation in vivo, Gene Ther., 2008, vol. 15, pp. 257-266. [cited by applicant]
Feichtinger et al., Sonoporation increases therapeutic efficacy of inducible and constitutive BMP2/7 in vivo gene delivery, Hum Gene Ther Methods, 2014, vol. 25, 57-71. [cited by applicant]
Ko et al., In situ tissue regeneration through host stem cell recruitment, Exp Mol Med, 2013, pp. 45-57. [cited by applicant]
Chaudhury, Mesenchymal stem cell applications to tendon healing, Muscles Ligaments Tendons J., 2012, vol. 2, pp. 222-229. [cited by applicant]
Rothrauff et al., Cellular therapy in bone-tendon interface regeneration, Organogenesis, 2014, vol. 10, pp. 13-28. [cited by applicant]
Extended Europen Search Report for EP 17760656 dated Oct. 15, 2019, 10 pages. [cited by applicant]
Hernot et al., Microbubbles in the ultrasound-triggered drug and gene delivery, Advanced Drug Delivery Reviews, 2008, vol. 60(10), pp. 1153-1166. [cited by applicant]
Ruschke et al., BMPs are mediators in tissue crosstalk of the regenerating musculoskeletal system, Cell and Tissue Research, 2012, vol. 347(3), pp. 521-544. [cited by applicant]
Marmotti et al., Bone marrow derived stem cellsw in joint and bone diseases: a concise review, International Orthopeadics, 2014, vol. 38(9), pp. 1787-1801. [cited by applicant]
Sonia et al., Strategies to engineer tendon/ligament-to-bone interface: Biomaterials, cells and growth factors, Advanced Drug Delivery Reviews, 2015, vol. 94, pp. 126-140. [cited by applicant]
CN OA for 201780013826.3 dated Sep. 21, 2020. [cited by applicant]
EPO Exam Report for Application No. 17760656.3 dated Aug. 4, 2020. [cited by applicant]
Tellado et al., Strategies to engineer tendon/ligament-to-bone interface: Biomaterials, cells and growth factors, Advanced Drug Delivery Reviews, 2015, vol. 94, pp. 126-140. [cited by applicant]
Shapiro et al., Therapeutic Gene Targeting To Endogenous Stem Cells For Bone Regeneration, 2014 Poster abstract, Orthopaedic Research Society (ORS) 60th Annual Meeting, New Orleans, LA, 2014. [cited by applicant]
International Search Report and Written Opinion of PCT/US2017/020033, Dated Jul. 27, 2017, 11 Pages. [cited by applicant]
Chen, G et al., Cell-free scaffolds with different stiffness but same microstructure promote bone regeneration in rabbit large bone defect model, Journal of Biomedical Materials Research. Part A, 2015, vol. 104(4), p. 8… [cited by applicant]
Kovacevic et al., Biological augmentation of rotator cuff tendon repair, Clin Orthop Relat Res., 2008, vol. 466, pp. 622-633. [cited by applicant]